Publication | Closed Access

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Chronic PhaseHematological MalignancyNilotinib Versus ImatinibMedicineMixed-phenotype Acute LeukemiaEnestnd TrialHematologyClinical TrialsPathologyMyeloid NeoplasiaOncologyCancer ResearchHealth Sciences